aTyr Pharma [LIFE] vs Zymeworks [ZYME] Detailed Stock Comparison
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: aTyr Pharma Inc wins in 12 metrics, Zymeworks Inc. wins in 5 metrics, with 0 ties. aTyr Pharma Inc appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | aTyr Pharma Inc | Zymeworks Inc. | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 14.35 | 3.79 | Zymeworks Inc. |
| Price-to-Book Ratio | -42.41 | 7.32 | Zymeworks Inc. |
| Debt-to-Equity Ratio | 0.62 | 6.80 | aTyr Pharma Inc |
| PEG Ratio | 8.46 | 0.05 | Zymeworks Inc. |
| EV/EBITDA | 16.72 | -20.40 | aTyr Pharma Inc |
| Profit Margin (TTM) | 18.36% | -76.56% | aTyr Pharma Inc |
| Operating Margin (TTM) | 22.23% | -1,755.55% | aTyr Pharma Inc |
| EBITDA Margin (TTM) | 22.23% | N/A | N/A |
| Return on Equity | 21.03% | -26.72% | aTyr Pharma Inc |
| Return on Assets (TTM) | 10.00% | -14.29% | aTyr Pharma Inc |
| Free Cash Flow (TTM) | $29.95M | $-35.36M | aTyr Pharma Inc |
| 1-Year Return | 200.19% | 80.58% | aTyr Pharma Inc |
| Price-to-Sales Ratio (TTM) | 2.65 | 18.46 | aTyr Pharma Inc |
| Enterprise Value | $1.31B | $1.73B | Zymeworks Inc. |
| EV/Revenue Ratio | 3.38 | 16.33 | aTyr Pharma Inc |
| Gross Profit Margin (TTM) | 98.13% | N/A | N/A |
| Revenue per Share (TTM) | $24 | $1 | aTyr Pharma Inc |
| Earnings per Share (Diluted) | $1.14 | $-1.08 | aTyr Pharma Inc |
| Beta (Stock Volatility) | N/A | 1.20 | N/A |
| Short % of Float | 9.90% | 8.16% | Zymeworks Inc. |
aTyr Pharma Inc vs Zymeworks Inc. Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| aTyr Pharma Inc | 5.41% | -1.44% | -24.23% | 37.77% | 2,153.42% | 2,064.47% |
| Zymeworks Inc. | 1.66% | -2.80% | -2.80% | -1.52% | -10.44% | -12.62% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| aTyr Pharma Inc | 200.19% | 537.14% | 246.89% | 457.50% | -69.84% | -64.02% |
| Zymeworks Inc. | 80.58% | 181.77% | -36.88% | 76.00% | 76.00% | 76.00% |
Performance & Financial Health Analysis: aTyr Pharma Inc vs Zymeworks Inc.
| Metric | LIFE | ZYME |
|---|---|---|
| Market Information | ||
| Market Cap | $1.03B | $1.96B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 497,145 | 626,460 |
| 90 Day Avg. Volume | 537,565 | 729,503 |
| Last Close | $16.45 | $23.26 |
| 52 Week Range | $0.64 - $32.50 | $11.51 - $29.75 |
| % from 52W High | -49.37% | -21.82% |
| All-Time High | $396.06 (Jun 01, 2015) | $59.03 (Jan 11, 2021) |
| % from All-Time High | -95.85% | -60.60% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.66% | -0.92% |
| Quarterly Earnings Growth | 1.57% | -0.92% |
| Financial Health | ||
| Profit Margin (TTM) | 0.18% | -0.77% |
| Operating Margin (TTM) | 0.22% | -17.56% |
| Return on Equity (TTM) | 0.21% | -0.27% |
| Debt to Equity (MRQ) | 0.62 | 6.80 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $-1.45 | $3.60 |
| Cash per Share (MRQ) | $2.00 | $3.10 |
| Operating Cash Flow (TTM) | $36.23M | $-33,005,000 |
| Levered Free Cash Flow (TTM) | $51.01M | $-12,959,125 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: aTyr Pharma Inc vs Zymeworks Inc.
| Metric | LIFE (Apr 24, 2026) | ZYME (Apr 13, 2026) |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 14.35 | 3.79 |
| Forward P/E | 8.46 | 33.43 |
| PEG Ratio | 8.46 | 0.05 |
| Price to Sales (TTM) | 2.65 | 18.46 |
| Price to Book (MRQ) | -42.41 | 7.32 |
| Market Capitalization | ||
| Market Capitalization | $1.03B | $1.96B |
| Enterprise Value | $1.31B | $1.73B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 3.38 | 16.33 |
| Enterprise to EBITDA | 16.72 | -20.40 |
| Risk & Other Metrics | ||
| Beta | N/A | 1.20 |
| Book Value per Share (MRQ) | $-1.45 | $3.60 |
Financial Statements Comparison: aTyr Pharma Inc vs Zymeworks Inc.
Financial Metrics
Loading Financial Charts...
Revenue
Operating Margin
Profit Margin
Long Term Debt
Income Flow Analysis
Financial Statements Comparison
Income Statement
| Metric | LIFE (2025) | ZYME (2025) |
|---|---|---|
| Revenue/Sales | 387.61M | 105.97M |
| Cost of Goods Sold | 6.73M | N/A |
| COGS % of Revenue | 1.7% | 0.0% |
| Gross Profit | 380.88M | N/A |
| Gross Margin | 98.3% | 0.0% |
| Research & Development | N/A | 137.00M |
| Operating Income (EBIT) | 72.92M | -92.54M |
| Operating Margin | 18.8% | -87.3% |
| EBITDA | 85.18M | -80.82M |
| EBITDA Margin | 22.0% | -76.3% |
| Pre-Tax Income | 75.74M | -79.75M |
| Pre-Tax Income % of Revenue | 19.5% | -75.3% |
| Income Tax | 4.59M | 1.38M |
| Income Tax % of Revenue | 1.2% | 1.3% |
| Net Income (Profit) | 71.15M | -81.13M |
| Profit Margin | 18.4% | -76.6% |
Balance Sheet & Liquidity Metrics
| Metric | LIFE (2025) | ZYME (2025) |
|---|---|---|
| Cash & Equivalents | 91.09M | 41.16M |
| Total Current Assets | 245.80M | 248.77M |
| Total Current Assets % of Revenue | 63.4% | 234.8% |
| Total Current Liabilities | 113.19M | 42.32M |
| Total Current Liabilities % of Revenue | 29.2% | 39.9% |
| Long-Term Debt | 1.23M | 14.80M |
| Long-Term Debt % of Revenue | 0.3% | 14.0% |
| Total Shareholders Equity | -24.12M | 268.50M |
| Retained Earnings | -102.51M | -953.16M |
| Retained Earnings % of Revenue | -26.4% | -899.5% |
| Property, Plant & Equipment | 2.32M | 29.56M |
Cash Flow Statement Comparison
| Metric | LIFE (2025) | ZYME (2025) |
|---|---|---|
| Operating Cash Flow | 38.96M | -40.00M |
| Operating Cash Flow % of Revenue | 10.1% | -37.7% |
| Capital Expenditures | -1.49M | -1.52M |
| Free Cash Flow | 29.95M | -35.36M |
| FCF Margin | 7.7% | -33.4% |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | -41.70M |
Short Interest & Institutional Ownership Analysis
| Metric | LIFE | ZYME |
|---|---|---|
| Shares Short | 2.26M | 4.08M |
| Short Ratio | 4.29 | 5.42 |
| Short % of Float | 9.90% | 8.16% |
| Shares Outstanding | 62.56M | 75.19M |
| Float Shares | 25.92M | 72.80M |
| % Held by Insiders | 6.31% | 1.26% |
| % Held by Institutions | 23.87% | 98.45% |
| % Held by Public | 69.82% | 0.29% |
Dividend Analysis & Yield Comparison: aTyr Pharma Inc vs Zymeworks Inc.
| Metric | LIFE | ZYME |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |